Small molecule · developed by Talphera
Sufentanil NanoTab is a sufentanil sublingual tablet formulation given as-needed for acute pain.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01660763 | Phase 3 | Post Operative Pain | Completed | TLPH |
| NCT01710345 | Phase 2 | Acute Pain | Completed | TLPH |
| NCT00612534 | Phase 2 | Post Operative Pain | Completed | TLPH |
| NCT01721070 | Phase 1 | Pharmacokinetics | Completed | TLPH |
| NCT01639729 | Phase 1 | Pharmacokinetics | Completed | TLPH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute PainPharmacokineticsPost Operative Pain
Updated Nov 1, 2026. Something wrong or missing? Report it on the TLPH page.
See TLPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLPH catalysts and pipeline →